Despite these limitations, this study provides meaningful information on the use and outcomes of crizotinib in a real‐world population of ALK‐positive metastatic NSCLC patients treated with crizotinib, by conducting a multicenter retrospective cohort in South Korea. The gene discussed is ALK; the disease is non-small cell lung carcinoma.